---
title: "InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303302918.md"
description: "InnoCare Pharma presented three orelabrutinib studies at ESMO Congress 2026. A Phase 2 trial combining orelabrutinib with zuberitamab showed an 89.5% response rate and durable responses in previously untreated marginal zone lymphoma, with manageable safety. Another Phase 2 study demonstrated sustained benefit in relapsed/refractory chronic lymphocytic leukemia. Additionally, a retrospective study found that adding orelabrutinib to rituximab deepened responses during maintenance treatment for intermediate- or high-risk marginal zone lymphoma."
datetime: "2026-10-28T00:30:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303302918.md)
  - [en](https://longbridge.com/en/news/303302918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303302918.md)
generator: "portal-rs"
---

# InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial

-   InnoCare Pharma presented results from three orelabrutinib studies at the European Society for Medical Oncology Congress 2026. \* A Phase 2 trial combining orelabrutinib with zuberitamab showed durable responses in previously untreated marginal zone lymphoma, with manageable safety. \* Another Phase 2 study showed sustained benefit in relapsed or refractory chronic lymphocytic leukemia, with favorable long-term safety. \* A retrospective study found orelabrutinib with rituximab deepened responses during maintenance treatment for intermediate- or high-risk marginal zone lymphoma. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610272030PRIMZONEFULLFEED9854775) on October 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [InnoCare's Orelabrutinib Combination Shows 100% Response Rate in Preliminary Phase 2 MZL Results](https://longbridge.com/en/news/302066175.md)
- [Three Orelabrutinib Studies Presented in Oral Sessions at the 88th Annual Meeting of the Japanese Society of Hematology](https://longbridge.com/en/news/302067089.md)
- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [InnoCare Pharma (SEHK:9969) Climbed, What Is Driving Attention Today?](https://longbridge.com/en/news/303497906.md)
- [InnoCare Pharma Reports Strong Orelabrutinib Data at ESMO](https://longbridge.com/en/news/303303500.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**